somapacitan
NN8640-4054
Phase 3 small_molecule completed
Quick answer
somapacitan for Growth Hormone Disorder is a Phase 3 program (small_molecule) at Novo Nordisk A/S with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Novo Nordisk A/S
- Indication
- Growth Hormone Disorder
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- completed